BREXIDOL ® is a Piroxicam-based drug
THERAPEUTIC GROUP: Non-steroidal anti-inflammatory and antirheumatic drugs
Indications BREXIDOL ® Piroxicam
BREXIDOL ® is indicated in the treatment of inflammatory joint pain present in rheumatic and traumatic pathologies.
BREXIDOL ® Piroxicam mechanism of action
BREXIDOL ® is a drug based on Piroxicam, an active ingredient belonging to the category of non-steroidal anti-inflammatory drugs and progenitor of the oxicam class, capable of ensuring topical absorption of the drug.
Pharmacokinetic studies show in fact how the application of medicated plasters can reduce the systemic absorption of Piroxicam compared to the oral drug, allowing instead its accumulation mainly in the synovial area, and thus guaranteeing a concentrated therapeutic action at the joint level.
The pain-relieving properties of Piroxicam are essentially due to the ability of this active ingredient to selectively inhibit cyclooxygenase 2, enzymes activated by inflammatory stimuli and involved in the synthesis of chemical mediators, known as prostaglandins, with pro-inflammatory and algogenic activity.
Recent studies have also attributed to this active ingredient a significant antioxidant and histoprotective action, linked to the ability to detoxify the tissue from hydrogen peroxide, thus protecting it both from oxidative damage induced by reactive oxygen species and from damage induced by enzymes with proteolytic activity overexpressed during inflammatory processes.
In addition to a mainly concentrated therapeutic action at the local level, the topical application of Piroxicam also allows to significantly reduce the side effects associated with oral therapy, and in particular those at the gastrointestinal level, thus ensuring greater tolerability.
Studies carried out and clinical efficacy
1.PROXICAM PATCHES IN POST-HERPETIC NEURALGIA
Ann Dermatol. 2011 May; 23: 162-9. Epub 2011 May 27.
Efficacy of Piroxicam patch compared to lidocaine patch for the treatment of postherpetic neuralgia.
Kim JY, Lim HJ, Lee WJ, Lee SJ, Kim do W, Kim BS.
Interesting work that demonstrates how the use of medicated Piroxicam patches can be more effective and above all safer than lidocaine patches, in the treatment of neuropathic pain such as post-herpetic neuralgia.
2. THE EXCELLENT COMPLIANCE OF PIROXICAM-MEDICATED PATCHES IN PATIENTS WITH OSTEOARTHRITIS
Arzneimittelforschung. 2009; 59: 403-9.
Efficacy and safety of Piroxicam patch versus Piroxicam cream in patients with lumbar osteoarthritis. A randomized, placebo-controlled study.
Allegrini A, Nuzzo L, Pavone D, Tavella-Scaringi A, Giangreco D, Bucci M, Toniato E, Mezzetti A, Martinotti S, Comuzio S, Di Grigoli M, Bonani S.
A study conducted on numerous patients suffering from osteoarthritis which has shown how the application of Piroxicam patches can be more effective and above all better accepted by patients than the use of creams. The best compliance is essentially due to the possibility of applying the patch once a day and not three times as in the case of creams.
3. MULTIFORM HERITEMA INDUCED BY PIROXICAM
Contact Dermatitis. 2004 Apr; 50: 263.
Piroxicam-induced erythema multiforme.
Prieto A, De Barrio M, Pérez C, Velloso A, Baeza ML, Herrero T.
Case report denouncing the onset of erythema multiforme following the topical application of Piroxicam. These studies emphasize the importance of contacting your doctor before taking this medicine.
Method of use and dosage
BREXIDOL ®
Piroxicam 14 mg medicated patches.
For the symptomatic treatment of joint painful states both on a rheumatic and traumatic basis, it is recommended to apply one patch a day to the intact skin in correspondence with the painful joint.
Therapy should not exceed 8 days.
In any case, it is recommended to consult your doctor before starting therapy with BREXIDOL ®
BREXIDOL ® Piroxicam warnings
Although BREXIDOL ® is a drug not subject to mandatory medical prescription, therefore freely salable, it would be advisable to consult your doctor before starting treatment with this drug.
Before applying the patch it would be advisable to cleanse the skin region and make sure there are no lesions or skin inflammations.
Repeated and prolonged use over time could expose the treated region to allergic reactions of a dermatological nature.
It is also recommended to avoid exposure of the treated region to sunlight, given the photosensitizing capacity of Piroxicam.
Patients suffering from hepatic, renal, coagulative and gastro-enteric diseases should pay particular attention to the intake of BREXIDOL ® and consult their doctor.
PREGNANCY AND BREASTFEEDING
Although the systemic absorption of Piroxicam during therapy with BREXIDOL ® is insignificant, the absence of clinical trials capable of evaluating the safety of this drug in the unborn child, when taken during pregnancy, obliges to extend the contraindications to use also during pregnancy. and the subsequent period of breastfeeding.
Interactions
The topical application of Piroxicam allows to reduce the risk of potential drug interactions with other active ingredients capable of varying both the efficacy of action and the safety profile to the point of elimination.
Contraindications BREXIDOL ® Piroxicam
The use of BREXIDOL ® is contraindicated in case of hypersensitivity to the active ingredient, to one of its excipients or to other NSAIDs, simultaneous use of anticoagulants or other non-steroidal anti-inflammatory drugs.
It is recommended not to apply BREXIDOL ® on injured or inflamed skin.
Undesirable Effects - Side Effects
The topical application of Piroxicam and the consequent low systemic absorption allow to significantly reduce the risk of adverse reactions generally associated with oral administration of the drug.
However, it is important to remember how the use of BREXIDOL ® can cause erythema, itching, burning, contact dermatitis and other dermatological reactions in the area where the patch is applied.
Given the photo-sensitizing properties of Piroxicam, it is advisable to avoid sun exposure throughout the therapy.
Note
BREXIDOL ® can be sold without a prescription.
The information on BREXIDOL ® Piroxicam published on this page may be out of date or incomplete. For a correct use of this information, see the Disclaimer and useful information page.
